ASHM @ CROI 2017

HEPATITIS C VIRUS: GONE BY 2030? John W. Ward, CDC, Atlanta, GA, USA Recognizing hepatitis C virus (HCV) as a major public health threat, the World

Comment: Abstract follows. Modelling studies presented at CROI in 2016 predicted that prompt treatment of Hepatitis C with direct acting antivirals (

 Comment: Abstract follows. For me, this was one of the most interesting studies presented at CROI this year. It generated much discussion among

  A few “Snapshots” from the Inflammation and Age-related Complications session, of interest:   1.       A

  Venous thromboembolism (VTE ) risk is increased in HIV patients (5.7 -11.00/1000 person years) compared to the general population (1.0/1000 pe

So far there have been two well documented cases of individuals on PrEP contracting HIV despite good adherence and high TDF levels. This poster presen

I tried something a little different this afternoon. The conference venue set up a simulcast of all concurrent sessions in a theatre-like venue with s

  Day 3 CROI:   I am sure all the General Practitioners reading this topic are much more familiar with the management of patients with th

           Cerebral small-vessel disease (CSVD) is a common problem with increasing age and accounts for approximately 2

Comment: The significant rise in symptomatic and asymptomatic STIs in recent years is having a huge impact on clinical practice. Many practices strug

Wednesday morning featured a series of oral presentations exploring the interplay of STIs and altered microbiomes might affect PrEP. Renee Heffron pr

Magnet is a nurse and peer led Sexual Health service in San Francisco. It recently co-located with Strut (San Francisco AIDS Foundation) and a number

      Symposium 5-3 ‘Strangers in the Night; Challenges and Opportunities in STI Control: provided a fascinating insight into po

Day 2 CROI My colleagues have already commented on the new HIV integrase strand transfer inhibitor, Bictegravir, so onto other potential new agents/f

  Since the advent of integrase inhibitors, bringing about our latest highly effective combination therapy, with viral suppression rat

Tuesdayy afternoon provided a session of poster presentations exploring the complicated relationship between ARV treatment , excess weight gain and he

  Dr Carl June presented how novel therapeutics have the potential for an HIV cure. His work in the development of Chimeric Antigen Receptor (CA

Comment: Abstract follows: Doravirine seeks to address the limitations of the currently available NNRTIs: avoidance of neuropsychiatric side effects,

Comment: Abstract follows: This study demonstrates non-inferiority of treatment switch to dolutegravir/rilpivirine at 48 weeks versus remaining on cu

Comment: See abstract below. This phase II study presents non-inferior results and several bictegravir phase III trials in both naïve and switch pati

Hi from Seattle.  Very interesting plenary this morning at 8.30 presented by Jintanat Ananworanich. She spoke about the potential and possible p

Greetings from Seattle. I would like to start by thanking ASHM for giving me the opportunity to attend this world-class conference and also thank the